TREATMENT OUTCOMES OF SECOND-LINE DOCETAXEL TREATMENT FOR ADVANCED NON-SMALL CELL LUNG CANCER FOLLOWING IMMUNOTHERAPY REGIMENS
Main Article Content
Abstract
Background: Immune checkpoint inhibitor-containing regimens represent standard first-line therapies for advanced non-small cell lung cancer (NSCLC). However, disease progression is frequent, necessitating effective second-line strategies. This study aimed to: (1) Describe clinical and subclinical characteristics of advanced NSCLC patients treated with second-line Docetaxel post-immunotherapy at K Hospital; (2) Evaluate treatment efficacy and safety profiles.
Methods: A retrospective longitudinal study evaluated 62 advanced NSCLC patients progressing after first-line immunotherapy and receiving second-line Docetaxel (75 mg/m² q3w) at K Hospital from January 2019 to April 2026. Efficacy was evaluated via RECIST v1.1, safety via CTCAE v5.0, and survival metrics via Kaplan-Meier.
Results: Mean age was 59.3 ± 8.4 years; 83.9% male; 80.6% smokers; 88.7% ECOG PS 0-1. Adenocarcinoma comprised 71.0% and squamous cell carcinoma 27.4%. First-line Pembrolizumab regimens accounted for 93.5%. Objective response rate (ORR) was 21.0% and disease control rate (DCR) was 48.4%. Median duration of response was 6.5 months. Median PFS was 3.93 months (95% CI: 2.57-5.29) with 1-year PFS of 26.3%. Median OS was 10.7 months (95% CI: 7.65-13.68) with 1-year OS of 44.7% and 2-year OS of 28.7%. Neutropenia was the predominant hematologic toxicity (62.9%, grade 3-4: 17.7%).
Conclusions: Second-line Docetaxel monotherapy post-immunotherapy offers promising disease control (DCR 48.4%, median OS 10.7 months) with manageable safety.
Keywords
Non-small cell lung cancer, Docetaxel, second-line immunotherapy, Pembrolizumab, K Hospital
Article Details
References
2. Herbst RS, Giaccone G, de Marinis F, et al. Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC. N Engl J Med. 2020;383(14):1328-1339.
3. Garitaonaindia Y, Calvo V, Redondo I, et al. Docetaxel as a subsequent line after progression to platinum-based chemotherapy and immunotherapy. JCO. 2023;41(16_suppl):e21197-e21197.
4. Bittoni MA, Keeping S, Carbone DP, et al. 81P Real-world experience with docetaxel regimens in metastatic non-squamous (mNSq) non-small cell lung cancer (NSCLC) patients previously treated with platinum-based chemotherapy (PCT) and an immune checkpoint inhibitor (ICI) in the United States (US). Immuno-Oncology and Technology. 2023;20.
5. Hettinger GCN, Long Q, Parikh RB. Real-World Effectiveness of Second-Line Therapies in Advanced Non-Small Cell Lung Cancer: Insights From Propensity-Weighted Comparative Analyses of Longitudinal EHR Data. Clinical Lung Cancer. 2026;27(2):227-236.e12.
6. Neal J, Pavlakis N, Kim S, et al. 60 CONTACT-01: Efficacy and safety from a phase III study of atezolizumab (atezo)+ cabozantinib (cabo) vs docetaxel (doc) monotherapy in patients (pts) with metastatic NSCLC (mNSCLC) previously treated with checkpoint inhibitors and chemotherapy. Journal of Thoracic Oncology. 2023;18(4):S39-S40.
7. Ghiringhelli F, Lawrence YR, Felip E, et al. Atezolizumab and bevacizumab, with or without radiotherapy, versus docetaxel in patients with metastatic non-small cell lung cancer previously treated with a checkpoint inhibitor and chemotherapy: results from the randomized, phase Ib/II MORPHEUS-Lung study. Journal for Immunotherapy of Cancer. 2025;13(8):e011892.
8. Pan H, Fang Y, Wu L. 1030P anlotinib plus docetaxel in the treatment of non-small cell lung cancer (NSCLC) after failure of previous immune checkpoint inhibitors (ICIs) therapy: updated results from a pooled analysis of two phase II trials. Annals of Oncology. 2022;33:S1026.